scholarly journals Postmarket Safety Surveillance of Delayed Complications for Recent FDA-Approved Hyaluronic Acid Dermal Fillers

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Joel L. Cohen ◽  
Jessica Hicks ◽  
Alessandra Nogueira ◽  
Vanessa Lane ◽  
Bill Andriopoulos
Polymers ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 948
Author(s):  
Nicola Zerbinati ◽  
Sabrina Sommatis ◽  
Cristina Maccario ◽  
Maria Chiara Capillo ◽  
Giulia Grimaldi ◽  
...  

(1) Background: Injectable hyaluronic acid (HA) dermal fillers are used to restore volume, hydration and skin tone in aesthetic medicine. HA fillers differ from each other due to their cross-linking technologies, with the aim to increase mechanical and biological activities. One of the most recent and promising cross-linkers is polyethylene glycol diglycidyl ether (PEGDE), used by the company Matex Lab S.p.A., (Brindisi, Italy) to create the HA dermal filler PEGDE family. Over the last few years, several studies have been performed to investigate the biocompatibility and biodegradability of these formulations, but little information is available regarding their matrix structure, rheological and physicochemical properties related to their cross-linking technologies, the HA content or the degree of cross-linking. (2) Methods: Seven different injectable HA hydrogels were subjected to optical microscopic examination, cohesivity evaluation and rheological characterization in order to investigate their behavior. (3) Results: The analyzed cross-linked dermal fillers showed a fibrous “spiderweb-like” matrix structure, with each medical device presenting different and peculiar rheological features. Except for HA non cross-linked hydrogel 18 mg/mL, all showed an elastic and cohesive profile. (4) Conclusions: The comparative analysis with other literature works makes a preliminary characterization of these injectable medical devices possible.


2021 ◽  
Vol 9 ◽  
pp. 2050313X2110251
Author(s):  
Michelle Aaron ◽  
Yu Qing Huang ◽  
Danielle Bouffard ◽  
Jean-Pascal Costa ◽  
Benoît Côté

A 66-year-old woman presented to the hospital with cutaneous necrosis of her right ankle and foot. Her symptoms began immediately after an intra-articular injection of hyaluronic acid for ankle osteoarthritis, which was performed 6 days before. Histopathology showed an intra-vascular hyaluronic acid embolus. The initial treatment approach was conservative, but the patient’s clinical state degraded. She was thus treated with sub-cutaneous hyaluronidase, the enzyme that degrades hyaluronic acid, which yielded a moderate improvement even though it was administered 22 days after the initial hyaluronic acid injection. Although hyaluronic acid embolism and subsequent cutaneous necrosis are well-known complications of dermal fillers, there are few reported cases of embolism following intra-articular injection. To our knowledge, this is the first time hyaluronidase has been used in this setting.


2021 ◽  
pp. 074880682199015
Author(s):  
Ian S. Lehrer ◽  
Joe Niamtu

Cosmetic facial surgery procedures and therapies have continued to evolve with an emphasis on minimally invasive techniques with a shorter recovery time. We present a how-to guide for nonsurgical rhinoplasty including the use of different hyaluronic acid fillers. We provide examples of before and after patient photos as well as photos demonstrating our technique. This technical note highlights the popular concept of minimally invasive nasal contouring using dermal fillers. As such, we provide a brief overview of different dermal fillers that can be used for this application, potential problems and complications, as well as remedies. Dermal fillers have become an entry point into cosmetic surgery for many patients. Our technique of nasal contouring with hyaluronic acid fillers in particular yields safe, effective, and repeatable results.


2019 ◽  
Vol 12 (8) ◽  
pp. e228882 ◽  
Author(s):  
Shivanshan Pathmanathan ◽  
Marcin Dzienis

A 52-year-old male patient with hyaluronic acid-based dermal fillers injected in his cheeks was diagnosed with glossotonsillary malignancy, and managed with concurrent cetuximab (epidermal growth factor receptor inhibitor) and radiation therapy. He developed significant inflammation around the dermal filler sites after first cycle of cetuximab which improved with dissolution of the dermal fillers with hyaluronidase. This suggests that cetuximab can lead to inflammation around the dermal filler sites, which can be treated with dissolution of the filler.


2020 ◽  
Vol 8 (4) ◽  
pp. e2753
Author(s):  
Zoya Diwan ◽  
Sanjay Trikha ◽  
Sepideh Etemad-Shahidi ◽  
Zunaid Alli ◽  
Christopher Rennie ◽  
...  

2020 ◽  
Vol 9 (7) ◽  
pp. 276-281
Author(s):  
Danielle Davy

Filler migration is a rare complication of dermal filler treatment. Although most research has found that more permanent fillers, such as silicone, are more likely to migrate due to their long-term presence in the body, there have also been reported cases of filler migration from short-term hyaluronic acid-based dermal fillers. As lip augmentation procedures are fast becoming one of the most frequently requested treatments in medical aesthetics, this article looks at the longevity of hyaluronic acid lip dermal fillers, while also aiming to assess the cause of dermal filler post-treatment migration and evaluating how to minimise its risk.


Sign in / Sign up

Export Citation Format

Share Document